Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine

NEW YORK, September 26, 2017 /PRNewswire/ --

If you want a Stock Review on AKRX, PCRX, RIGL, or LPCN then come over to and sign up for your free customized report today. On Monday, September 25, 2017, the NASDAQ Composite ended the trading session at 6,370.59, down 0.88%; the Dow Jones Industrial Average edged 0.24% lower, to finish at 22,296.09; and the S&P 500 closed at 2,496.66, slightly dropping 0.22%. Losses were broad based as seven out of nine sectors ended the day in negative. This Tuesday, has initiated reports coverage on the following Drugs - Generic equities: Akorn Inc. (NASDAQ: AKRX), Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Lipocine Inc. (NASDAQ: LPCN). Look at the free research reports issued today on for these stocks by signing up at:


Lake Forest, Illinois headquartered Akorn Inc.'s stock finished Monday's session 0.15% higher at $33.11 with a total trading volume of 977,633 shares. The Company's shares have advanced 13.31% over the past twelve months, and 51.67% since the start of this year. The stock is trading above its 200-day moving average by 16.65%. Additionally, shares of Akorn, which develops, manufactures, and markets specialized generic and branded pharmaceuticals, OTC drug products, and animal health products in the US and internationally, have a Relative Strength Index (RSI) of 52.07. Sign up and read the free research report on AKRX at:

Pacira Pharmaceuticals 

On Monday, shares in Parsippany, New Jersey headquartered Pacira Pharmaceuticals Inc. recorded a trading volume of 417,678 shares. The stock ended the session 0.81% higher at $37.50. The Company's shares have advanced 16.10% on an YTD basis. The stock is trading below its 50-day moving average by 3.69%. Moreover, shares of Pacira Pharma, which develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the US, have an RSI of 52.19.

On September 07th, 2017, research firm Oppenheimer initiated a 'Perform' rating on the Company's stock. The complimentary research report on PCRX can be downloaded at:

Rigel Pharma 

South San Francisco, California-based Rigel Pharmaceuticals Inc.'s shares closed the day 0.42% lower at $2.36. The stock recorded a trading volume of 1.09 million shares, which was above its three months average volume of 720.74 thousand shares. The stock is trading below its 50-day moving average by 1.94%. Additionally, shares of Rigel Pharma, which engages in the discovery and development of drugs in the therapeutic areas of immunology, oncology, and immuno-oncology, have an RSI of 44.75. Register for free on and access the latest report on RIGL at:


Shares in Salt Lake City, Utah headquartered Lipocine Inc. finished the day flat at $4.14. The stock recorded a trading volume of 76,149 shares. The Company's shares have advanced 12.50% on an YTD basis. The stock is trading above its 200-day moving average by 4.89%. Furthermore, shares of Lipocine, which develops pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health, have an RSI of 50.52. Get free access to your research report on LPCN at:

Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email . Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.